Patent Exclusivity Reform Needed Due To Difficult Drug Environment – Hassan
Executive Summary
The fixed post-approval exclusivity period should be extended in light of the lengthening of the development process, Schering-Plough CEO Fred Hassan suggested during an interview with "The Pink Sheet"
You may also be interested in...
FDA Needs Communications Make-Over, Execs Say; Commish May Be First Step
FDA should expand and improve its external communications programs, panelists said during the FDA Alumni Association annual meeting in Washington, D.C. April 5
Drugs Should Get Longer Patents In Exchange For More Safety Data – Wood
Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said
Schering Seeks Salvation In External Deals; Hassan Outlines Licensing Plan
The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1